Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Wählen Sie die gewünschte Spezies
Mouse (Murine) PLAUR Protein expressed in Human Cells - ABIN2007425
Dear, Medcalf: The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. in European journal of biochemistry / FEBS 1998
Show all 3 Pubmed References
Human PLAUR Protein expressed in HEK-293 Cells - ABIN2713801
Ge, Siegel, Jordan, Naumann: Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures. in Biophysical journal 2014
The results establish GDE3 (zeige GDPD2 Proteine) as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI (zeige GPI Proteine)-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior.
The ratio of full-length versus cleaved uPAR as analysed by Western blotting and its regulation was assessed by addition of different protease inhibitors and transforming growth factor - beta1 (TGF-beta1 (zeige TGFB1 Proteine)). The role of uPAR cleavage in cell proliferation and migration was analysed using real-time cell analysis and invasion was assessed using the myoma invasion model
Plg-RKT is required for plasminogen (zeige PLG Proteine) binding and macrophage migration in vivo
The synergy of circulating factor suPAR and APOL1 (zeige APOL1 Proteine) G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.
Results identify soluble uPAR as a functional connection between the bone marrow and the kidney, and they implicate bone marrow immature myeloid cells as a key source of soluble uPAR that leads to glomerular dysfunction.
Plaur deficiency does not increase susceptibility to epileptogenesis after traumatic brain injury in an animal model.
Significance of the urokinase-type plasminogen activator (zeige PLAU Proteine) and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Findings indicate a significant correlation of uPAR cleavage with breast cancer progression, but the precise biological consequence(s) of the cleavage or the cleavage products still remains to be elucidated.
interaction of full-length suPAR with alphavbeta3 integrin expressed on podocytes results in down-modulation of nephrin (zeige NPHS1 Proteine) that may affect kidney functionality in different human pathologies characterized by increased concentration of suPAR.
In an in vivo murine angiogenesis model uPAR-deficient PTEN heterozygous animals increased the impaired angiogenic phenotype of uPAR knockout mice and were able to reverse the high invasive potential of PTEN heterozygotes.
results demonstrated that PLAUR induces geftinib-resistance through EGFR (zeige EGFR Proteine)/p-AKT (zeige AKT1 Proteine)/survivin (zeige BIRC5 Proteine) signaling pathway in gefitinib-resistant human lung adenocarcinoma cells. PLAUR could be a novel therapeutic target for gefitinib-resistant NSCLC patients.
High Upar expression is associated with breast cancer.
Circulating soluble uPAR levels are higher in patients with peripheral arterial disease, particularly in those with extensive atherosclerosis and are predictive of long term cardiovascular and PAD-related outcomes.
Data confirmed PLAUR and CDH11, both targets of miR (zeige MLXIP Proteine)-335, to be overexpressed in gastric cancer tissues.
the present study demonstrated that EGF (zeige EGF Proteine) induced aggressiveness of gastric cancer cells by activating epithelial to mesenchymal transition, which involved the activation of the ERK1/2 pathway and, subsequently, uPAR expression
The results establish GDE3 (zeige GDPD2 Proteine) as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI (zeige GNPDA1 Proteine)-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior.
uPAR and TF could potentially be attractive targets for molecular imaging and therapy in oral squamous cell carcinoma due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival.
These findings may show that presenting a high level of suPAR in migraine patients with attack and aura results to predisposition to occurring on the symptoms and that high levels of suPAR, procalcitonin and fibrinogen in patients with migraine result in neurogenic inflammation during migraine headaches.
IFN-gamma (zeige IFNG Proteine), CXCL16 (zeige CXCL16 Proteine) and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in systemic lupus erythematosus.
Main associations between PLAUR (urokinase plasminogen activator receptor) single nucleotide polymorphisms (SNPs) and markers of airway remodelling, and immunohistochemical analyses
Data show that urokinase-type plasminogen activator (uPA (zeige PLAU Proteine)) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA (zeige PLAU Proteine) receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1 (zeige SERPINE1 Proteine)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA (zeige PLAU Proteine)/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
Data indicate that superoxide dismutase (SOD) inhibited high glucose (HG)-induced expression of uPAR and VEGF in bovine retinal microvascular endothelial cell (REC).
These data indicated that E. coli LPS (zeige IRF6 Proteine) led to an increase in u-PA (zeige PLAU Proteine) activity and RNA expression of u-PA (zeige PLAU Proteine) and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
the interaction between uPAR and Man-6-P/IGF2R (zeige IGF2R Proteine) is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R (zeige IGF2R Proteine) by different mechanisms.
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.
urokinase plasminogen activator surface receptor
, plasminogen activator, urokinase receptor
, urokinase plasminogen activator receptor
, urokinase-type plasminogen activator receptor
, monocyte activation antigen Mo3
, u-plasminogen activator receptor form 2
, urokinase-type plasminogen activator (uPA) receptor
, plasminogen activator urokinase receptor 3
, urinary plasminogen activator receptor 2
, urinary plasminogen activator receptor 3